Aethlon Medical (NASDAQ:AEMD) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research report report published on Saturday. The firm issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Aethlon Medical in a research note on Friday, November 15th.

Aethlon Medical Stock Performance

AEMD stock opened at $0.64 on Friday. Aethlon Medical has a fifty-two week low of $0.24 and a fifty-two week high of $2.10. The stock’s 50 day simple moving average is $0.50 and its 200 day simple moving average is $0.43. The company has a market cap of $8.87 million, a P/E ratio of -0.23 and a beta of 1.61.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.